Product
Ingavirin
2 clinical trials
5 indications
Indication
InfluenzaIndication
HumanIndication
Acute Respiratory InfectionIndication
ColdIndication
COVID-19Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children Aged 6 Months to 2 Years With Influenza and Other Acute Respiratory Viral Infections Against Standard TherapyStatus: Completed, Estimated PCD: 2022-04-29
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19Status: Completed, Estimated PCD: 2022-01-12